Dapivirine

Drug Profile

Dapivirine

Alternative Names: AIDS-105293; Dapivirine ring 004; R-147681; TMC-120

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tibotec BVBA
  • Developer International Partnership for Microbicides; Janssen Infectious Diseases BVBA
  • Class Antivirals; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 21 Sep 2017 International Partnership for Microbicides and Gilead Sciences withdraws the phase II REACH study for HIV-1 infection (Prevention, In volunteers, In adolescent, In adult) in South Africa prior to enrolment, as it was transferred to partner who will conduct under its own IND (NCT03074786)
  • 10 Aug 2017 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV infections in USA and Thailand (NCT03239483)
  • 02 Aug 2017 International Partnership for Microbicides and National Institutes of Health plan a phase I trial for HIV-1 infections (Prevention) (NCT03234400)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top